A special multidisciplinary session on ovarian cancer took place during the European Congress on Gynaecological Oncology, in Athens, with the aim of predicting what will happen in the field of ovarian cancer in the near [more]
Results from studies on PARP inhibitors show that BRCA status and responsiveness to platinum analogues are much less binding that it was thought to achieve some improvements. But more clinical trials are needed to decide if PARP inhibitors should be used as part of first-line therapy or reserved for a later line [more]
Testing for hereditary mutations that increase the risk of cancer is important for risk reduction, early detection and choice of treatment. Ephrat Levy-Lahad offers an overview of what we know ‒ and what remains uncertain [more]
PARP inhibitors are the first class of drugs to exploit a new concept in oncology – synthetic lethality. Alexandra Leary explains the rationale, reviews the trial evidence and clinical experience, and looks to their future [more]
Treatment of advanced-stage ovarian cancer should comprise optimal debulking surgery followed by adjuvant intraperitoneal chemotherapy. Steven Narod, from Women’s College Research Institute, Toronto, Canada, argues that widespread adoption of this model would increase cure rates [more]
Selected Reports by Janet Fricker Download full article
Selected reports edited by Janet Fricker Download full article
Deciding to start a family is the most momentous decision many people will ever take. For someone living with a cancer diagnosis, new life can seem particularly important, but it also carries particular risks. Download [more]
Working at a massive hospital in a country with high rates of advanced women’s cancers gave Vesna Kesic the ideal opportunity to hone her skills as a gynaecological oncology surgeon. Thanks to her commitment to [more]
Selected reports edited by Janet Fricker Download full article
The treatment of ovarian cancer and management of advanced ovarian cancer have progressed over the past few decades through several key milestones, including improvements in surgery, the evolution of chemotherapy and the establishment of an [more]
Selected repor ts edited by Janet Fricker Download full article